IL-17-expressing cells as a potential therapeutic target for treatment of immunological disorders

Pharmacological Reports

Volumn 63, Issue 1, 2011, Pages 30-44

  Strzȩpa, Anna ^a   Szczepanik, Marian ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Asthma; Autoimmunity; Cancer; IL 17; T cells; Therapy; Vaccination

Indexed keywords

AIN 457; ANTIINFLAMMATORY AGENT; APILIMOD; AROMATIC HYDROCARBON RECEPTOR; BRIAKINUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 17 RECEPTOR FC FUSION PROTEIN; LISINOPRIL; LY 2439821; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID RELATED ORPHAN RECEPTOR GAMMA; SIMVASTATIN; UNCLASSIFIED DRUG; USTEKINUMAB;

ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; ASTHMA; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; COLITIS; CROHN DISEASE; CYTOKINE RELEASE; DRUG MECHANISM; DRUG TARGETING; ENTERITIS; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOPATHOLOGY; IMMUNOREGULATION; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TH17 CELL; TUMOR GROWTH; VACCINATION;

EID: 79953170980     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70396-6     Document Type: Review

References (115)

1. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F: Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol, 2007, 8, 942-949 (Pubitemid 47300008).
2. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL: Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem, 2003, 278, 1910-1914 (Pubitemid 36801431).
3. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E et al.: Phenotypic and functional features of human Th17 cells. J Exp Med, 2007, 204-1861.
4. Bai A, Lu N, Guo Y, Liu Z, Chen J, Peng Z: All-trans retinoic acid down-regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis. J Leukoc Biol, 2009, 86, 959-969.
5. Benveniste EN: Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med, 1997, 75, 165-173.
6. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 2006, 441, 235-238.
7. Boe A, Baiocchi M, Carbonatto M, Papoian R, Serlupi- Crescenzi O: Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine, 1999, 11, 1057-1064 (Pubitemid 30045345).
8. Brereton CF, Sutton CE, Lalor SJ, Lavelle EC, Mills KH: Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease. J Immunol, 2009, 183, 1715-1723.
9. Brok HP, van Meurs M, Blezer E, Schantz A, Peritt D, Treacy G, Laman JD et al.: Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol, 2002, 169, 6554-6563 (Pubitemid 36903508).
10. Brown GD, Herre J, Williams DL, Willment JA, Marshall AS, Gordon S: Dectin-1 mediates the biological effects of β-glucans. J Exp Med, 2003, 197, 1119-1124 (Pubitemid 36570067).
11. Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, Shafran I et al.: A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis, 2006, 12, 558-565 (Pubitemid 43977736).
12. Bush KA, Farmer KM, Walker JS, Kirkham BW: Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum, 2002, 46, 802-805 (Pubitemid 34214263).
13. Carmody RJ, Ruan Q, Liou HC, Chen YH: Essential roles of c-Rel in TLR-induced IL-23 p19 gene expression in dendritic cells. J Immunol, 2007, 178, 186-191 (Pubitemid 46033600).
14. Chabaud M, Fossiez F, Taupin JL, Miossec P: Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol, 1998, 161, 409-414 (Pubitemid 28285549).
15. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P: Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine, 2000, 12, 1092-1099 (Pubitemid 30479493).
16. Chen Y, Thai P, Zhao YH, Ho YS, DeSouza MM, Wu R: Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem, 2003, 278, 17036-17043 (Pubitemid 36799579).
17. Chen Z, Tato CM, Muul L, Laurence A, O'Shea JJ: Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum, 2007, 56, 2936-2946 (Pubitemid 47502740).
18. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J et al.: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin- 1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 2002, 46, 614-624 (Pubitemid 34214243).
19. Cohn L, Elias JA, Chupp GL: Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol, 2004, 22, 789-815 (Pubitemid 38680442).
20. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L et al.: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature, 2003, 421, 744-748 (Pubitemid 36227625)
21. DeLyria ES, Redline RW, Blanchard TG: Vaccination of mice against H. pylori induces a strong Th-17 response and immunity that is neutrophil dependent. Gastroenterology, 2009, 136, 247-256.
22. Doodes PD, Cao Y, Hamel KM, Wang Y, Farkas B, Iwakura Y, Finnegan A: Development of proteoglycan-induced arthritis is independent of IL-17. J Immunol, 2008, 181, 329-337.
23. Evans HG, Suddason T, Jackson I, Taams LS, Lord GM: Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci USA, 2007, 104, 17034-17039 (Pubitemid 350210986).
24. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ et al.: T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med, 1996, 183, 2593-2603 (Pubitemid 26193037).
25. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM: Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med, 2003, 197, 1107-1117 (Pubitemid 36570066).
26. Gerosa F, Baldani-Guerra B, Lyakh LA, Batoni G, Esin S, Winkler-Pickett RT, Consolaro MR et al.: Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med, 2008, 205, 1447-1461 (Pubitemid 351831499).
27. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID: Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax, 2002, 57, 875-879 (Pubitemid 35178612).
28. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 2005, 6, 1123-1132 (Pubitemid 41541790).
29. He D, Wu L, Kim HK, Li H, Elmets CA, Xu H: CD8+ IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. J Immunol, 2006, 177, 6852-6858 (Pubitemid 44715050).
30. He D, Wu L, Kim HK, Li H, Elmets CA, Xu H: IL-17 and IFN-γ mediate the elicitation of contact hypersensitivity responses by different mechanisms and both are required for optimal responses. J Immunol, 2009, 183, 1463-1470.
31. Hellings PW, Vandekerckhove P, Claeys R, Billen J, Kasran A, Ceuppens JL: Progesterone increases airway eosinophilia and hyper-responsiveness in a murine model of allergic asthma. Clin Exp Allergy, 2003, 33, 1457-1463 (Pubitemid 37289945).
32. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH: TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol, 2006, 177, 7980-7989 (Pubitemid 44846315).
33. Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, Heemskerk B, Wrzesinski C, Borman ZA et al.: Type 17 CD8+ T cells display enhanced antitumor immunity. Blood, 2009, 114, 596-599.
34. Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, Gold R: Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol, 2005, 237, 123-130 (Pubitemid 43117208).
35. Hong K, Chu A, Ludviksson BR, Berg EL, Ehrhardt RO: IL-12, independently of IFN-γ, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol, 1999, 162, 7480-7491 (Pubitemid 29277728).
36. + Tc17 cells with reduced cytotoxic activity. Eur J Immunol, 2009, 39, 1716-1725.
37. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, Maruoka M et al.: IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J, 2001, 20, 5332-5341.
38. Infante-Duarte C, Horton HF, Byrne MC, Kamradt T: Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol, 2000, 165, 6107-6115.
39. Ito Y, Usui T, Kobayashi S, Iguchi-Hashimoto M, Ito H, Yoshitomi H, Nakamura T et al.: Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum, 2009, 60, 2294-2303.
40. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR: The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell, 2006, 126, 1121-1133 (Pubitemid 44380299).
41. H17 cells in multiple sclerosis. Ann Neurol, 2009, 66, 390-402.
42. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel- Moreno J, Cilley GE, Shen F et al.: IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol, 2007, 8, 369-377 (Pubitemid 46745412).
43. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J: Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol, 2008, 144, 200-207 (Pubitemid 351287002).
44. Kimura A, Naka T, Kishimoto T: IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA, 2007, 104, 12099-12104 (Pubitemid 47185636).
45. Klemann C, Raveney BJ, Klemann AK, Ozawa T, von Horsten S, Shudo K, Oki S, Yamamura T: Synthetic retinoid AM80 inhibits Th17 cells and ameliorates experimental autoimmune encephalomyelitis. Am J Pathol, 2009, 174, 2234-2245.
46. Kolls JK, Linden A: Interleukin-17 family members and inflammation. Immunity, 2004, 21, 467-476 (Pubitemid 39370503).
47. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y: IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol, 2006, 177, 566-573 (Pubitemid 43939170).
48. + T cells producing IL-17. J Immunol, 2009, 182, 1794-1798.
49. H17 cells. Nature, 2007, 448, 484-487.
50. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S et al.: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest, 1999, 103, 1345-1352 (Pubitemid 29218305).
51. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM: IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med, 2008, 205, 1535-1541 (Pubitemid 351962016).
52. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W: Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol, 2007, 178, 6730-6733 (Pubitemid 46847396).
53. Krysiak R, Okopień B: Pleiotropic effects of angiotensin- converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol Rep, 2008, 60, 514-523.
54. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T et al.: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med, 2005, 201, 233-240 (Pubitemid 40189432).
55. LeibundGut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, Schweighoffer E et al.: Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol, 2007, 8, 630-638 (Pubitemid 46785127).
56. Letuve S, Lajoie-Kadoch S, Audusseau S, Rothenberg ME, Fiset PO, Ludwig MS, Hamid Q: IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts. J Allergy Clin Immunol, 2006, 117, 590-596 (Pubitemid 43340223).
57. Li H, Chen J, Huang A, Stinson J, Heldens S, Foster J, Dowd P et al.: Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Proc Natl Acad Sci USA, 2000, 97, 773-778 (Pubitemid 30070385).
58. Lin Y, Slight SR, Khader SA: Th17 cytokines and vaccine-induced immunity. Semin Immunopathol, 2010, 32, 79-90.
59. Liu SJ, Tsai JP, Shen CR, Sher YP, Hsieh CL, Yeh YC, Chou AH et al.: Induction of a distinct CD8 Tnc17 subset by transforming growth factor-β and interleukin-6. J Leukoc Biol, 2007, 82, 354-360.
60. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A et al.: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med, 2002, 8, 500-508 (Pubitemid 34546753).
61. Lu YJ, Gross J, Bogaert D, Finn A, Bagrade L, Zhang Q, Kolls JK et al.: Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog, 2008, 4, e1000159.
62. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB: Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum, 2004, 50, 650-659 (Pubitemid 38198849).
63. Majewska M, Bryniarski K, Ptak M, Zaja̧c K, Zemelka M, Lobo FM, Ptak W, Szczepanik M: Role of TLR ligands in epicutaneously induced contrasuppression. Pharmacol Rep, 2009, 61, 539-549.
64. Manel N, Unutmaz D, Littman DR: The differentiation of human TH-17 cells requires transforming growth factor- β and induction of the nuclear receptor RORγt. Nat Immunol, 2008, 9, 641-649 (Pubitemid 351714729).
65. H17 lineage. Nature, 2006, 441, 231-234.
66. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B et al.: Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med, 2004, 351, 2069-2079 (Pubitemid 39482500).
67. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P et al.: T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity, 2009, 31, 787-798.
68. Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M: Interleukin-17-producing γδ T cells selectively expand in response to pathogen products and environmental signals. Immunity, 2009, 31, 321-330.
69. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H: Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler, 1999, 5, 101-104 (Pubitemid 29186827).
70. McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, Finder JD et al.: Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene- α and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol, 2005, 175, 404-412 (Pubitemid 40884344).
71. H-17 cell-mediated pathology. Nat Immunol, 2007, 8, 1390-1397.
72. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, Olivenstein R et al.: IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol, 2001, 108, 430-438 (Pubitemid 32881066).
73. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H: Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science, 2007, 317, 256-260 (Pubitemid 47076203).
74. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, Sekikawa K et al.: Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity, 2002, 17, 375-387 (Pubitemid 35279557).
75. Nakae S, Nambu A, Sudo K, Iwakura Y: Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol, 2003, 171, 6173-6177 (Pubitemid 37467240).
76. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med, 1995, 182, 1281-1290.
77. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD et al.: Interleukin-17 promotes angiogenesis and tumor growth. Blood, 2003, 101, 2620-2627 (Pubitemid 36857622).
78. Numasaki M, Lotze MT, Sasaki H: Interleukin-17 augments tumor necrosis factor-α-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett, 2004, 93, 39-43 (Pubitemid 38591518).
79. O'Connor W, Jr., Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, Kolls JK, Flavell RA: A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol, 2009, 10, 603-609.
80. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C et al.: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet, 2008, 371, 1675-1684 (Pubitemid 351671884).
81. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB: In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol, 2006, 176, 1908-1915.
82. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK et al.: Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci USA, 2009, 106, 14948-14953.
83. Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, Luger D, Nussenblatt RB, Caspi RR: Cutting edge: NKT cells constitutively express IL-23 receptor and RORγt and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol, 2008, 180, 5167-5171.
84. Roark CL, French JD, Taylor MA, Bendele AM, Born WK, O'Brien RL: Exacerbation of collagen-induced arthritis by oligoclonal, IL-17-producing γδ T cells. J Immunol, 2007, 179, 5576-5583.
85. Romano M, D'Souza S, Adnet PY, Laali R, Jurion F, Palfliet K, Huygen K: Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine, 2006, 24, 3353-3364.
86. Samoilova EB, Horton JL, Hilliard B, Liu TS, Chen Y: IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol, 1998, 161, 6480-6486 (Pubitemid 28562184).
87. Sanjabi S, Hoffmann A, Liou HC, Baltimore D, Smale ST: Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci USA, 2000, 97, 12705-12710.
88. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH: Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol, 2008, 7, 796-804.
89. Shi G, Cox CA, Vistica BP, Tan C, Wawrousek EF, Gery I: Phenotype switching by inflammation-inducing polarized Th17 cells, but not by Th1 cells. J Immunol, 2008, 181, 7205-7213.
90. + T cells by cyclic AMP-dependent signal transduction pathway. Cytokine, 1998, 10, 841-850.
91. Slack EC, Robinson MJ, Hernanz-Falcon P, Brown GD, Williams DL, Schweighoffer E, Tybulewicz VL, Reis e Sousa C: Syk-dependent ERK activation regulates IL-2 and IL-10 production by DC stimulated with zymosan. Eur J Immunol, 2007, 37, 1600-1612 (Pubitemid 46939495).
92. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet, 2008, 371, 987-997 (Pubitemid 351392039).
93. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH: Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells, amplifying Th17 responses and autoimmunity. Immunity, 2009, 31, 331-341.
94. Takeda K, Akira S: Toll-like receptors in innate immunity. Int Immunol, 2005, 17, 1-14.
95. Tang J, Zhu W, Silver PB, Su SB, Chan CC, Caspi RR: Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signature and is driven by unique effector mechanisms: initial encounter with autoantigen defines disease phenotype. J Immunol, 2007, 178, 5578-5587 (Pubitemid 46674353).
96. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD: Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol, 1998, 111, 645-649 (Pubitemid 28452327).
97. Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J, Tocker J, Peschon J: Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol, 2006, 177, 36-39 (Pubitemid 43939112).
98. H2 cells. Nat Immunol, 2009, 10, 864-871.
99. Vaknin-Dembinsky A, Balashov K, Weiner HL: IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol, 2006, 176, 7768-7774 (Pubitemid 43849078).
100. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger B: The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature, 2008, 453, 106-109 (Pubitemid 351630329).
101. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B: TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL- 17-producing T cells. Immunity, 2006, 24, 179-189 (Pubitemid 43214587).
102. H-17 responses. Nat Immunol, 2008, 9, 650-657.
103. Wada Y, Lu R, Zhou D, Chu J, Przewloka T, Zhang S, Li L et al.: Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood, 2007, 109, 1156-1164 (Pubitemid 46220663).
104. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B et al.: Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol, 2007, 8, 950-957 (Pubitemid 47300009).
105. H17 cells. Nature, 2008, 454, 350-352.
106. Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, Wang YH et al.: Regulation of inflammatory responses by IL-17F. J Exp Med, 2008, 205, 1063-1075 (Pubitemid 351679682).
107. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, Shah B et al.: Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity, 2008, 29, 44-56.
108. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, Ma L et al.: T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity, 2008, 28, 29-39.
109. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI, Spriggs MK: Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity, 1995, 3, 811-821 (Pubitemid 26091152).
110. Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, Lowes MA, Krueger JG: Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol, 2009, 124, 1022-1030 e. 395.
111. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S: Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol, 2008, 180, 6988-6996.
112. Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK: Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis, 2006, 12, 382-388.
113. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham- Anderson J, Wu J, Ouyang W: Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature, 2007, 445, 648-651 (Pubitemid 46232884).
114. Zhou L, Ivanov, II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE et al.: IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol, 2007, 8, 967-974 (Pubitemid 47300011).
115. H17 cell differentiation by antagonizing RORγt function. Nature, 2008, 453, 236-240.